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Introduction
Alkaline phosphatase (ALP) is expressed in a wide 
variety of tissues and exists as four different isoenzymes, 
each coded by a different gene. These four isoenzymes 
are termed the tissue-non-specific (also known as 
liver-bone-kidney ALP) intestinal, placental and germ 
cell forms.1 The three latter types are often grouped 
together under the term “tissue-specific ALP”. The four 
isoenzymes can be distinguished from each other via 
their genes of origin and via their response to specific 
inhibitors. Thus, tissue-non-specific ALP is inhibited by 
levamisole, histidine and homoarginine, while the 
tissue-specific isoforms are not.2,3 The tripeptide, Phe-
Gly-Gly, is able to inhibit the tissue-specific ALPs, but 
not the tissue-non-specific isoform.4 Serum levels of ALP 
have commonly been used for disease diagnosis, with 
the tissue-non-specific isoforms acting as markers of 
bone and liver pathology.5
All adipose tissue depots are known to contain 
preadipocytes. Preadipocytes undergo adipogenesis, 
a finely regulated process of differentiation into mature 
adipocytes. Involved factors in this process include both 
positive and negative stimuli that incorporate a variety 
of hormones, enzymes and nutrients.6,7 Adipogenesis 
can be influenced by fat depot origin in in vitro models. 
For example, preadipocytes that are isolated from the 
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Abstract
Background: Alkaline phosphatase (ALP) controls intracellular lipid accumulation in human preadipocytes, but it is 
not known whether ALP is expressed in all body fat depots, or whether it has a similar role at all sites. 
Design: Cross-sectional. 
Setting and subjects: Subjects undergoing breast reduction and abdominal fat biopsies operations at Charlotte 
Maxeke Johannesburg Academic Hospital.
Outcome measures: This study compared intracellular lipid accumulation and ALP activity in the presence and 
absence of ALP inhibitors in preadipocytes that were obtained from different adipose depots. Abdominal and 
mammary gland preadipocytes were isolated from women and induced to differentiate in culture. ALP activity 
and intracellular lipid levels were measured at baseline and after 12 days of differentiation in the presence and 
absence of the ALP inhibitors, histidine and levamisole. 
Results: ALP activity was detected in nondifferentiated abdominal (134 ± 7.5 mU/mg protein) and mammary gland 
(136 ± 9.6 mU/mg protein) preadipocytes. Its activity had increased significantly (p-value < 0.0005 for both) by day 
12 of differentiation (388 ± 55 for abdominal and 278 ± 28 mU/mg protein for mammary). Preadipocytes treated 
with histidine had lower fat accumulation (p-value < 0.0005) and ALP activity (p-value < 0.005) than nontreated 
cells on day 12, while those treated with levamisole had lower fat accumulation (p-value < 0.005), but elevated 
ALP activity (p-value < 0.05), compared to nontreated cells. Lipid accumulation (p-value < 0.005) and ALP activity 
(p-value < 0.05) were higher in abdominal than mammary gland preadipocytes by day 12. 
Conclusion: ALP is involved in the control of intracellular lipid accumulation in human preadipocytes that are 
isolated from both adipose depots. The ability of levamisole to inhibit this process while activating ALP, suggests 
that this molecule acts via an ALP-independent pathway, while histidine attenuates both lipid deposition and ALP 
activity. 
 Peer reviewed. (Submitted: 2012-10-03. Accepted: 2012-12-10.) © SEMDSA JEMDSA 2013;18(1):58-64
Original Research: Lipid accumulation and alkaline phosphatase activity in human preadipocytes
59 2013 Volume 18 No 1JEMDSA
visceral depot differentiate more slowly, compared 
with subcutaneous preadipocytes.8 
Previously, we demonstrated a positive correlation 
between ALP activity and fat accumulation in murine 
3T3-L1 preadipocytic cells9 and human mammary 
gland preadipocytes.10 The ability of ALP inhibitors 
to pharmacologically inhibit intracellular lipid 
accumulation suggests that ALP may play a role in 
preadipocyte lipid storage.9,10 It is not known whether 
ALP is expressed in other body fat depots, or whether 
it is involved in the molecular control of adipogenesis 
at such sites. Abdominal subcutaneous adipose tissue 
is an important fat storage depot and may influence 
whole body insulin sensitivity.11 Thus, some, but not all 
studies, have shown that it is a more important regulator 
of insulin resistance than the visceral fat depot.12,13 It has 
also been suggested that subcutaneous adipose tissue 
may play a role as a “reservoir” for triglyceride storage, 
and may act to limit fat deposition in the visceral 
depot.11,14 Therefore, it is important to understand the 
molecular events that are implicated in the control 
of lipid deposition in abdominal subcutaneous 
preadipocytes and mature adipocytes. Thus, in the 
current study, preadipocytes were isolated from 
mammary gland and abdominal subcutaneous fat 
depots to assess any differences in adipogenesis and 
ALP activity between these tissue sites.
Subjects and method
Reagents
All tissue culture reagents were purchased from 
Invitrogen Corporation, Scotland, and all other 
laboratory reagents were purchased from Sigma-
Aldrich, South Africa, unless otherwise stated.
Subjects
Human abdominal subcutaneous tissue samples were 
obtained voluntarily from 13 black women of mean 
body mass index (BMI) 38 ± 7.4 (range 29.3-53.5) and 
mean age 46.5 ± 6.5 (range 35-58). Mammary adipose 
tissue was obtained from 14 black women of mean BMI 
25.1 ± 1.6 (range 22-26.7, p-value < 0.0001 vs. abdominal) 
and mean age 45.7 ± 5 (range 38-55, p-value = 0.77 vs. 
abdominal). The latter participants underwent elective 
surgery for mammary gland reduction. 
Abdominal subcutaneous fat was collected under 
local anaesthetic. A transverse skin incision was made 
in the mid-right abdominal side of each volunteer. 
An incision length of 10-12 mm was sufficient to 
collect the required amount of fat. Haemostasis was 
secured with diathermy and the wound was closed 
with subcutaneous absorbable sutures. Both groups 
were admitted to surgery wards in Charlotte Maxeke 
Johannesburg Academic Hospital, Johannesburg.
All subjects were healthy, as assessed by history and 
physical examination. No pregnant subjects were 
included in the study. Informed consent was obtained 
before surgical intervention. Ethical approval to use 
the adipose tissue was obtained from the University of 
the Witwatersrand, Faculty of Health Sciences Human 
Ethics Committee. 
Isolation and culture of preadipocytes from abdominal 
subcutaneous and mammary gland adipose tissue 
Preadipocytes were isolated from adipose tissue using 
collagenase digestion, as described in a previously 
published method.15 The preadipocytes were grown 
in six well tissue culture plates at a density of 4 x 105 
cells per well, in a tissue culture medium, comprising 
Dulbecco’s Modified Eagle Medium (DMEM)-Ham’s 
F12 medium, containing 15 mM HEPES and 2 mmol/l 
glutamine, supplemented with 10% foetal bovine serum 
and 100 U/ml penicillin and 100 µg/ml streptomycin. 
After overnight culture, the cells were washed in DMEM-
Ham’s F12 medium. Subsequently, the medium was 
changed every third day, until the cells were confluent. 
The preadipocytes were stimulated to differentiate 
over 12 days in differentiation medium supplemented 
with 100 nmol/l hydrocortisone, 66 nmol/l insulin, 
0.5 mmol/l 3-isobuty-1-methylxanthine and 1 nmol/l 
triiodo-1-thyronine. The preadipocytes were incubated 
at 37oC in a humidified atmosphere with 5% CO2. The 
culture media were changed every three days. 
Alkaline phosphatase inhibitors
Preadipocytes were cultured in the absence or 
presence of ALP inhibitors. These inhibitors were added 
at the beginning of each differentiation period. 
The tissue-non-specific ALP inhibitors, histidine2 and 
levamisole,3 and the tissue-specific ALP inhibitor, Phe-
Gly-Gly,4 were used at concentrations of 20 mmol/l, 
2 mmol/l and 20 mmol/l, respectively. These doses 
were based on a previous study using the murine 3T3-
L1 preadipocyte cell line.9 
ALP activity and intracellular lipid accumulation were 
measured before intracellular lipid accumulation 
was initiated (day 0), and 12 days after stimulation of 
adipogenesis in preadipocytes isolated from all study 
subjects. These variables were also measured in the 
presence of the ALP inhibitors, but not in all subjects. 
Thus, the effect of histidine was measured in abdominal 
preadipocytes isolated from 10 subjects and in 
mammary gland preadipocytes from four subjects. 
The effect of levamisole was assessed in abdominal 
preadipocytes isolated from four subjects, and in 
mammary gland preadipocytes from nine subjects. The 
effect of Phe-Gly-Gly was measured in preadipocytes 
sequestered from the mammary tissue of four subjects, 
but not tested in the abdominal cells. 
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Measurement of alkaline phosphatase activity
Preadipocyte cell extracts were isolated at baseline 
(day 0) and 12 days after initiation of adipogenesis, 
using a previously published method.16 ALP activity was 
measured in these cell extracts using an automated 
colorimetric assay (Roche Diagnostics, Germany). The 
protein content of the supernatant was analysed using 
the Bradford method.17 The ALP activity was calculated 
as mU of activity per mg of cell protein. 
Measurement of adipogenesis
Intracellular fat accumulation, the hallmark of 
adipogenesis, was measured on day 0 and day 12 
using the Oil Red O technique.18 This method depends 
on the ability of the lipid droplets in the adipocyte to 
absorb the red dye, which is then extracted from the 
cells using isopropyl alcohol, and the absorbance 
measured at 510 nm. Lipid levels were expressed as 
optical density (OD) units per mg of cell protein. 
Statistical analysis
ALP activity and adipogenesis levels were expressed as 
mean ± standard error of mean (SEM). Differences in 
ALP activity or cellular fat accumulation within different 
treatment regimens were analysed using Student’s 
paired t-test. Analysis of covariance (ANCOVA), with 
adjustment for BMI, was used to compare cellular lipid 
and ALP levels between the preadipocytes isolated from 
the abdominal subcutaneous and mammary gland 
adipose tissue. The relationship between the change in 
ALP activity and the change in intracellular lipid levels 
over the 12-day incubation period was assessed by 
calculating the percentage change in both variables, 
and by implementing a univariate Pearson correlation 
analysis. This was performed on combined data from 
the abdominal and mammary gland preadipocytes 
and on data from each individual body site. Pearson 
correlation was also used to analyse the relationship of 
intracellular lipid and ALP levels with BMI. All statistical 
analyses were carried out using Statistica® version 9 
(StatSoft, USA). 
Results 
ALP activity was detected in undifferentiated 
human preadipocytes from both mammary gland 
and subcutaneous abdominal adipose depots. 
Enzymatic activity in these cells increased during the 
12-day differentiation period and was paralleled by 
an increase in cellular fat accumulation. Significant 
differences (p-value < 0.0005) for both these variables 
were detected between differentiated preadipocytes 
on day 12, and undifferentiated preadipocytes on 
day 0 (Figure 1). On day 0, lipid and ALP activity levels 
were similar in the two different preadipocyte cell 
populations. However, on day 12, both lipid (p-value 
< 0.005, Figure 1 a) and ALP activity (p-value < 0.05, 
Figure 1 b) levels were higher in the abdominal than 
those in the mammary preadipocytes.
Figure 2 shows the effect of histidine treatment on 
intracellular lipid levels and ALP activity in abdominal 
and mammary gland preadipocytes. With histidine 
treatment, intracellular lipid levels were significantly 
higher for all preadipocyte populations on day 12, 
compared to day 0 (Figure 2 a). Histidine treatment led 
to lower levels of lipid (p-value < 0.005 for mammary 
and p-value < 0.0005 for abdominal) on day 12 in 
treated, compared to untreated, cells. The level of 
ALP activity on day 12 was significantly higher (p-value 
< 0.005 for mammary and p-value < 0.05 for abdominal), 
than that observed on day 0 for preadipocytes 
that were not treated with histidine. However, with 
histidine treatment, ALP activity decreased significantly 
(p-value < 0.005 for both) from day 0 to day 12 in both 
preadipocyte populations (Figure 2 b). The activity 
of ALP in both abdominal depot- and mammary 
gland-derived cells was significantly lower in histidine-
treated preadipocytes (p-value < 0.005), compared to 
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Data are shown as a mean ± standard error of mean 
***p-value < 0.0005 vs. day 0, +: p-value < 0.05, ++: p-value < 0.005 vs. mammary gland
Abd: abdominal, ALP: alkaline phosphatase, Mam: mammary gland, OD: optical 
density
Figure 1: Comparison of (a) lipid accumulation and (b) 
alkaline phosphatase activity in human preadipocytes isolated 
from mammary gland (n = 14, light bars) and abdominal 
subcutaneous (n = 13, dark bars) adipose tissue
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Figure 3 shows the effect of levamisole treatment on 
intracellular lipid levels and ALP activity in abdominal 
and mammary gland preadipocytes. Preadipocytes 
from both fat depots, treated or nontreated with 
levamisole, had higher lipid levels on day 12 than 
on day 0 (Figure 3 a). Treatment with levamisole 
caused the cells to accumulate fewer lipids by day 12 
(p-value < 0.005 for preadipocytes from both depots), 
compared to nontreated cells (Figure 3 a). Abdominal 
preadipocytes, whether treated or not treated with 
levamisole, had higher lipid levels than preadipocytes 
from the mammary gland by day 12 (Figure 3 a). In the 
presence or absence of levamisole, and irrespective 
of fat depot source, ALP activity was higher in 
preadipocytes on day 12 than on day 0 (see Figure 3 
b). On day 12, ALP activity was higher (p-value < 0.005 
for mammary and p-value < 0.05 for abdominal) in 
levamisole-treated, than in nontreated, cells (Figure 3 
b). 
Treating the collected preadipocytes from the 
mammary gland with the tissue-specific ALP inhibitor, 
Phe-Gly-Gly, showed no effect on alkaline phosphate 
activity (322 ± 29 vs. 321 ± 25 mU/mg protein for 
nontreated, and treated, cells, respectively) or lipid 
accumulation (1.96 ± 0.10 vs. 1.90 ± 0.09 OD units/mg 
protein for nontreated, and treated, cells, respectively) 
by day 12. Comparing the results on day 12 with those 
on day 0 (lipid level was 0.42 ± 0.01 OD units/mg protein 
and ALP activity was 143 ± 11 mU/mg protein), it was 
found that there was a significant increase in both lipid 
accumulation (p-value < 0.005 for both treated and 
nontreated cells) and ALP activity (p-value < 0.005 for 
both treated and nontreated cells).
Correlation analysis on combined data from both 
body sites demonstrated a strong positive relationship 
(r = 0.66, p-value < 0.0001, n = 27) between the 
percentage change in ALP activity and the percentage 
change in intracellular lipid levels in preadipocytes that 
were not treated with ALP inhibitors. When this analysis 
was performed separately on preadipocytes taken 





















































































Data are shown as a mean ± standard error of mean 
*:p-value < 0.05, **:p-value < 0.005, ***:p-value < 0.0005 vs. day 0; ++: p-value < 0.005, +++: 
p-value < 0.0005 vs. preadipocytes treated with histidine
Abd: abdominal, ALP: alkaline phosphatase, -H: those not treated with histidine, +H: 
those treated with histidine, Mam: mammary gland, OD: optical density
Figure 2: The effect of histidine on (a) lipid accumulation and 
(b) alkaline phosphatase activity in human preadipocytes (n = 4 
for mammary and n = 10 for abdominal). The darker paired bars 
represent preadipocytes not treated (-H), while the lighter bar 
represents those treated (+H) with histidine for mammary gland 



















































































Data are shown as mean ± standard error of mean
*:p-value < 0.05, **:p-value < 0.005, ***:p-value < 0.0005 vs. day 0; +:p-value < 0.05, 
++:p-value < 0.005 vs. preadipocytes treated with levamisole; #:p-value < 0.05 vs. 
abdominal preadipocytes
Abd: abdominal, ALP: alkaline phosphatase, -L: not treated with levamisole, +L: 
treated with levamisole, Mam: mammary gland, OD: optical density
Figure 3: The effect of levamisole on (a) lipid accumulation and 
(b) alkaline phosphatase activity in human preadipocytes (n = 9 
for mammary and n = 4 for abdominal). The darker paired bars 
represent preadipocytes not treated with levamisole (-L), while 
the lighter bar represents those treated (+L) with levamisole for 
mammary gland and abdominal preadipocytes on day 12
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n = 14) and the abdominal depot (r = 48, p-value = 
0.09, n = 13), a stronger correlation was noted in the 
former preadipocyte population. Pearson correlation 
showed that BMI did not relate to intracellular lipid or 
ALP levels in either abdominal (r = -0.37, p-value = 0.21; 
r = -0.46, p-value = 0.11, respectively) or mammary 
gland (r = -0.37, p-value = 0.21; r = -0.16, p-value = 
0.59, respectively) preadipocytes after 12 days of 
culture. When data for these two adipose depots were 
combined, there was still no correlation of BMI with lipid 
(r = 0.30, p-value = 0.13) or ALP (r = 0.10, p-value = 0.64) 
levels. 
Discussion
The present study is the first to show that ALP is 
expressed in preadipocytes isolated from human 
abdominal subcutaneous fat tissue, and that the 
level of intracellular lipid accumulation is higher in 
subcutaneous abdominal preadipocytes, compared 
to that in preadipocytes taken from the mammary 
gland.
It has previously been shown that ALP is expressed 
in both the 3T3-L1 murine preadipocyte cell line and 
human preadipocytes from the mammary gland, and 
that ALP activity increases in conjunction with increased 
cellular fat accumulation.9,10 The present study has 
confirmed the parallel relationship between elevated 
ALP enzyme activity and cellular fat accumulation 
in abdominal subcutaneous adipose tissue. The 
intracellular deposition of lipid is the defining feature 
of the maturation of preadipocytes into adipocytes, a 
process termed “adipogenesis”. Therefore, it is possible 
that ALP may be a modulator of adipogenesis. Other 
studies have shown that ALP, which is a ubiquitously 
expressed enzyme, plays a pivotal role in tissue 
development,19 cellular differentiation20 and osteoblast 
cell mineralisation.21
Treatment of human preadipocytes with the tissue-
non-specific ALP inhibitor, histidine,2 blocked both 
intracellular lipid accumulation and ALP activity. 
Paradoxically, treating human preadipocytes with 
levamisole, which is also a tissue-non-specific ALP 
inhibitor,3 decreased intracellular lipid accumulation, 
but stimulated alkaline phosphatase activity. When 
human preadipocytes were incubated with a tissue-
specific ALP inhibitor, Phe-Gly-Gly,4 no inhibition of 
either fat accumulation or ALP activity was observed. 
The inhibition of ALP activity by histidine, but the lack 
of inhibition with Phe-Gly-Gly, would suggest that the 
enzyme isoform that is present in both fat depots is 
of the tissue-non-specific variety. Results from 3T3-L1 
cells using ALP inhibitors and PCR demonstrate that 
it is the tissue-non-specific isoform that is expressed 
in this cell type.9 The ability of levamisole to increase 
ALP activity in human preadipocytes has been 
reported previously,10 and a study of rat hepatocytes, 
which are known to express the tissue-non-specific 
ALP isoform, also showed a similar effect.22 It should 
be noted that levamisole inhibits ALP activity in cell 
extracts of human preadipocytes.10 This confirms that 
it is the tissue-non-specific form. Thus, levamisole only 
activates ALP activity in human preadipocytes with 
intact membranes,10 suggesting that this process is 
modulated by factors residing in the cell membrane 
system, the identities of which are currently unknown. 
The ability of levamisole to block intracellular lipid 
accumulation, but at the same time to increase ALP 
activity, counters the hypothesis that functional ALP 
is required for cellular lipid accretion. However, it is 
possible that in human preadipocytes, levamisole 
inhibits intracellular lipid accumulation at a point 
downstream of ALP, and this may block any feedback 
inhibition of ALP by factors downstream of this point, 
thus leading to the rise in ALP activity that was observed 
in this study. The fact that levamisole is able to inhibit 
ALP activity in murine 3T3-L1 cells suggests either that 
this cell line does not express the molecule responsible 
for mediating the ALP stimulatory effect, or that the 
murine homologue is not bound by levamisole. The 
mechanism by which levamisole inhibits adipogenesis 
in human adipocytes is not known, but investigating 
its method of action may be invaluable for a more 
complete understanding of the molecular events that 
are implicated in the adipogenic pathway. 
Despite the effects of levamisole on ALP activity and 
adipogenesis that were observed in the current study, 
there is good evidence that ALP plays an important 
role in intracellular lipid accumulation. Thus, a strong 
positive correlation between the percentage change 
in ALP activity and the percentage change in cellular 
lipid accumulation was observed in our study. It is also 
important to note that ALP is expressed in preadipocytes 
isolated from different species and tissues, including rat 
adipose tissue,23 human preadipocytes,10 adipocyte 
precursor cells in human bone marrow,24 rabbit 
preadipocytes,25 murine bone marrow preadipocytes26 
and adipocytes from chicken bone marrow.27 Previous 
studies have shown that ALP is located on lipid droplets 
in 3T3-L1 cells,9 human preadipocytes10 and HepG2 
cells.28 The latter is a human hepatocyte cell line, that 
like primary human hepatocytes, is able to accumulate 
lipid within a membrane-bound droplet, similar to that 
observed in adipocytes.29 These data demonstrate that 
ALP is expressed in cells that are able to accumulate 
lipid within specialised organelles, and its location on 
the surface of these lipid droplets is further evidence of 
the input of ALP into cellular lipid storage. 
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Furthermore, a previous study has shown that 
treating 3T3-L1 and HepG2 cells with small interfering 
RNA designed specifically to knock out ALP mRNA 
translation leads to reduced intracellular lipid 
accumulation.30 Additionally, in mice that harboured 
a tissue-non-specific ALP gene knockout, severe bone 
pathology, as well as an almost complete lack of 
adipose tissue, were observed.31 Lastly, in humans, a 
recent study demonstrated that polymorphisms in the 
tissue-non-specific ALP gene are associated with body 
fat distribution.32 
Intracellular lipid accumulation and ALP activity 
were only measured at baseline and on day 12 of 
the differentiation period. The latter represents a time 
point at which all the proteins that are characteristic 
of mature adipocytes are already being expressed.33 
Therefore, from the current experiments it is not possible 
to determine whether ALP function is required for the 
initiation of the adipogenic process, or is only necessary 
at the later stages of this pathway. The intracellular 
location of the ALP molecule at the surface of the lipid 
droplet suggests that it may assist in the formation of 
this organelle, a process which occurs at the terminal 
section of the differentiation pathway, the early 
portion of which (within the first hour) is characterised 
by a cascade of transcription factor gene expression.34 
Evidence that ALP acts at a later stage of adipogenesis 
derives from experiments performed in 3T3-L1 and 
HepG2 cells, whose treatment with the ALP inhibitors, 
histidine and levamisole, demonstrated that although 
intracellular lipid accumulation was reduced, the 
expression of peroxisome proliferator-activated 
receptor γ, a transcription factor that plays a key role 
in initiating adipogenesis, was not altered.28 In order 
to determine the exact point at which ALP functions 
within the adipogenic pathway, further experiments 
are required in which ALP expression is monitored 
immediately after adipogenesis has been initiated, 
and ALP inhibitors are added at specific time points. 
The present study is the first to demonstrate that 
intracellular lipid accumulation and ALP activity 
are higher in abdominal than mammary gland 
preadipocytes. This makes physiological sense as the 
abdominal subcutaneous adipose depot is a major 
storage site for lipid, whereas the mammary gland is not. 
Previously, depot-specific differences in adipogenesis 
have been observed, with preadipocytes isolated 
from visceral adipose tissue differentiating more slowly 
than those isolated from the subcutaneous abdominal 
depot.8 No studies have assessed the ALP activity 
within preadipocytes from the visceral fat depot. It is 
important to study the regulation of adipogenesis in 
the different body fat depots because it is known that 
visceral adipose tissue is more strongly associated with 
adverse metabolic risk factors than subcutaneous 
adipose tissue,35,36 whilst gluteofemoral adiposity is 
protective.37 Thus, an understanding at the molecular 
level of the regulation of fat storage in these adipose 
depots may have implications for the treatment of 
obesity-associated metabolic disorders.
The principal drawback of this study is that the agents 
that were used to inhibit ALP activity were not ALP-
specific. Each of the inhibitors has effects other than 
those on ALP, which may mediate their ability to block 
intracellular lipid accumulation. However, it should 
be noted that these inhibitors are sufficiently specific 
to have been routinely used to differentiate between 
the tissue-specific and tissue-non-specific isoenzymes 
of ALP.2-5 In addition, and as noted previously, there 
is excellent evidence from other studies9,10,28,30-32 of the 
involvement of ALP in intracellular lipid accumulation. 
A further weakness of this study was that the two 
groups of subjects from whom abdominal or mammary 
gland adipose tissue were isolated were not matched 
for BMI. This was countered by including BMI as a 
covariate within the ANCOVA model when comparing 
ALP activity and intracellular lipid levels between the 
preadipocytes that were isolated from the two body 
fat depots. Furthermore, no correlation was observed 
between BMI and preadipocyte lipid or ALP levels. 
Therefore, it is unlikely that the observed differences in 
these two variables after 12 days of tissue culture were 
because of the higher BMI of the subjects from whom 
the abdominal preadipocytes were isolated. 
Some of the performed experiments using ALP inhibitors 
were repeated on only four different preadipocyte 
preparations. However, statistically significant effects 
were still observed, suggesting that the experiments 
were not compromised by the low n number. 
Furthermore, a previous study that used 3T3-L1 cells 
also showed that the effects of the ALP inhibitors were 
very strong. Significant inhibition was observed after 
only three repeats.9 However, it should be noted that in 
the current study, correlation analyses performed using 
data from the individual body sites with n numbers of 
only 13 or 14 may not have been sufficiently powered 
to detect truly significant correlations, so these results 
should be interpreted with some caution. 
Conclusion
The differences in observed lipid accumulation 
between abdominal subcutaneous preadipocytes 
and preadipocytes from mammary gland adipose 
tissue may relate to differences in intracellular ALP 
activity. The ability of histidine to inhibit both ALP activity 
and intracellular lipid accumulation suggests that the 
antiobesity properties of this amino acid are mediated 
by both central and peripheral effects. However, the 
peripheral effects of histidine must be confirmed in 
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animal models. The observed relationship between ALP 
activity and cellular fat accumulation suggests that 
ALP plays a pivotal role in cellular fat accumulation in 
human preadipocytes that are isolated from adipose 
tissue at both body sites. 
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